Table 2 The performances of PCR-RDB genotyping cotesting and Cervista® cotesting for identifying CIN3+. (N = 24,819)
|  | PCR-RDB cotesting | Cervista® cotesting | P-value |
|---|---|---|---|
Arm 1 (n = 3272) | |||
 Sensitivity | 94.9% (87.9–100.0%) | 86.5% (75.5–97.5%) | 0.020 |
 Specificity | 90.6% (89.6–91.6%) | 92.7% (91.8–93.6%) | 0.002 |
 PPV | 10.8% (7.9–13.0%) | 11.9% (7.3–12.1%) | 0.760 |
 NPV | 99.9% (99.8–100.0%) | 99.7% (99.6–99.9%) | 0.046 |
 PLR | 10.2 (8.8–11.5) | 12.0 (9.9–14.2) | / |
 NLR | 0.06 (0.01–0.22) | 0.15 (0.06–0.33) | / |
 No. of cases identified at first round screening | 37 | 32 | / |
 No. of cases identified at follow-up round | 2 | 5 | / |
 No. of colposcopies to identified 1 case at first round | 9.1 | 8.4 | / |
 Cost per each identified CIN3+ women per round | $ 4860 (¥ 34,020) | $ 5122 (¥ 35,854) | / |
Arm 2 (n = 11,638) vs. Arm 3 (n = 9909)a | |||
 Sensitivity | 95.1% (92.5–97.7) | 80.9% (75.5–86.3) | < 0.001 |
 Specificity | 92.2% (91.7–92.7) | 95.0% (94.6–95.4) | < 0.001 |
 PPV | 22.1% (19.6–24.5) | 25.4% (22.0–28.7) | 0.121 |
 NPV | 99.9% (99.8–99.9) | 99.6% (99.5–99.7) | < 0.001 |
 PLR | 12.4 (11.3–13.0) | 16.5 (14.3–18.1) | / |
 NLR | 0.05 (0.03–0.09) | 0.20 (0.15–0.27) | / |
 No. of cases identified at first round screening | 252 | 165 | / |
 No. of cases identified at follow-up round | 21 | 43 | / |
 No. of colposcopies to identified 1 case at first round | 4.5 | 3.9 | / |
 Cost per each identified CIN3+ women per round | $ 2430 (¥ 17,010) | $ 2711 (¥ 18,977) | / |